Follow-up recommendations for patients with American Joint Committee on cancer stages I-III malignant melanoma

Cancer

Volumn 86, Issue 11, 1999, Pages 2252-2258

  Poo Hwu, Wen Jen ^a,d   Ariyan, Stephan ^a   Lamb, Lynne ^a   Papac, Rose ^a   Zelterman, Daniel ^a   Hu, Grace L ^a,c   Brown, Janis ^a   Fischer, David ^a   Bolognia, Jean ^a   Buzaid, Antonio C ^a,b  

^a YALE CANCER CENTER   (United States)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c NOVARTIS PHARMA AG   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cutaneous melanoma; Follow up recommendation; Medical oncology; Recurrence detection

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL PROTOCOL; CONSULTATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT EDUCATION; PRACTICE GUIDELINES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 12944273605     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991201)86:11<2252::AID-CNCR12>3.0.CO;2-Q     Document Type: Article

References (23)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Rigel DS. Malignant melanoma: perspectives on incidence and its effects on awareness, diagnosis, and treatment. Cancer 1996;46:195-8.
3. American Joint Committee on Cancer. Manual for staging of cancer. 2nd ed. Philadelphia: JB Lippincott, 1983:117-22.
4. American Joint Committee on Cancer. AJCC cancer staging manual, 5th ed. Philadelphia: JB Lippincott-Raven, 1997: 163-7.
5. Balch CM, Cascinelli N, Drzewiecki KT, Eldh J, MacKie RM, McCarthy WH, et al. A comparison of prognostic factors world wide. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, editors. Cutaneous melanoma. Philadelphia: JB Lippincott, 1992:188-92.
6. Ariyan S, Poo WJ, Bolognia JL, Buzaid AC, Ariyan T. Multiple primary melanomas: data and significance. Plast Reconstr Surg 1995;96:1384-9.
7. Romero JB, Stefanato CM, Kopf AW, Bart RS. Follow-up recommendations for patients with Stage I malignant melanoma. J Dermatol Surg Oncol 1994;20:175-8.
8. Martini L, Brandani P, Chiarugi C, Reali UM. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow-up schedule. Tumori 1994;80:188-97.
9. McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous Stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988;166:497-502.
10. Reintgen DS, Cox C, Slingluff CL, Seigier HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992;28:45-9.
11. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995; 274:1703-5.
12. Buzaid AC, Sandler AB, Mani S, Curtis A, Poo WJ, Bolognia JL, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993;11:638-43.
13. McEwan L, Smith JG, Matthews JP. Late recurrence of localized cutaneous melanoma: its influence on follow-up policy. Plast Reconstr Surg 1990;86:527-34.
14. Pearlman NW, Takach TJ, Robinson WA, Ferguson J, Cohen AL. A case-control study of late recurrence of malignant melanoma. Am J Surg 1992;164:458-61.
15. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance: patient or physician based? Ann Surg 1995;221: 566-71.
16. Kersey PA, Iscoe NA, Gapski JAP, Osoba D, From L, DeBoer G, et al. The value of staging and serial follow-up investigations in patients with completely resected primary, cutaneous malignant melanoma. Br J Surg 1985;72:614-7.
17. Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol 1985;13:756-60.
18. Soong S-J, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998;67:228-33.
19. Jillella A, Mani S, Nair B, Poo WJ, Bolognia J, Ariyan S, et al. The role for close follow-up of AJCC Stage I-III melanoma patients who remain clinically free of disease: preliminary analysis of the Yale experience. Proc ASCO 1995;14:413.
20. Poo WJ, Ariyan S. Patient vs. physician follow-up for melanoma: a clarification. JAMA 1996;276:450-1.
21. Sasson HN, Poo WJ, Henderson-Bakas M, Ariyan S. Prolonged survival in patients with advanced melanoma treated with neoadjuvant chemotherapy followed by resection. Ann Plast Surg 1996;37:286 -92.
22. Ross MI. Staging evaluation and surveillance for melanoma patients in a fiscally restrictive medical environment. Surg Clin North Am 1996;76:1423-32.
23. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 79;2361-70.